ArticleJournal of substance abuse treatment2021
Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder.
Article in Journal of substance abuse treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Global perspectives on telemedicine-enabled medications for opioid use disorder: Practices, priorities, and barriers.Journal of telemedicine and telecare · 2026Article
- Virtual Primary Care for People With Opioid Use Disorder: Scoping Review of Current Strategies, Benefits, and Challenges.Journal of medical Internet research · 2024Article
- Unmet need for medication for opioid use disorder among persons who inject drugs in 23 U.S. cities.Drug and alcohol dependence · 2024Article
- State guidance and system changes related to COVID-19: Impact on opioid treatment programs.Journal of substance use and addiction treatment · 2024Article
- Navigating addiction treatment during COVID-19: policy insights from state health leaders.Health affairs scholar · 2024Article
- Perceptions of COVID-19 risk during the pandemic: perspectives from people seeking medication for opioid use disorder.Annals of medicine · 2023Article
- Developing a Theoretically Informed Implementation Model for Telemedicine-Delivered Medication for Opioid Use Disorder: Qualitative Study With Key Informants.JMIR mental health · 2023Article
- Regulatory flexibilities and access to COVID-19 vaccines during the pandemic in Bhutan.Exploratory research in clinical and social pharmacy · 2022Article
- Practical Technology for Expanding and Improving Substance Use Disorder Treatment: Telehealth, Remote Monitoring, and Digital Health Interventions.The Psychiatric clinics of North America · 2022Review
- Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities.Addiction science & clinical practice · 2022Article
- Cross-Addiction Risk Profile Associations with COVID-19 Anxiety: a Preliminary Exploratory Study.International journal of mental health and addiction · 2022Article
- Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program.Drug and alcohol dependence reports · 2022Article
- Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia.Journal of substance abuse treatment · 2022Article
- MTrials · 2022Article
- "No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston.Journal of substance abuse treatment · 2022Article
- The NCSBN 2022 Environmental Scan: Resiliency, Achievement, and Public Protection.Journal of nursing regulation · 2022Article
- Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration.Journal of substance abuse treatment · 2021Article
- Opioid Use Disorder and COVID-19: Treatment and Recovery Factors among Vulnerable Populations at the Intersection of Two U.S. Epidemics.Journal of psychoactive drugsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The U.S. government declared the opioid epidemic as a national public health emergency in 2017, but regulatory frameworks that govern the treatment of opioid use disorder (OUD) through pharmaceutical interventions have remained inflexible. The emergence of the COVID-19 pandemic has effectively removed regulatory restrictions that experts in the field of medications for opioid use disorder (MOUD) have been proposing for decades and has expanded access to care. The regulatory flexibilities implemented to avoid unnecessary COVID-related death must be made permanent to ensure that improved access to evidence-based treatment remains available to vulnerable individuals with OUD who otherwise face formidable barriers to MOUD. We must seize this moment of COVOD-19 regulatory flexibilities to demonstrate the feasibility, acceptability, and safety of delivering treatment for OUD through a low-threshold approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.